Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates

Blood

Volumn 120, Issue 7, 2012, Pages 1357-1366

  Pandrea, Ivona ^a   Cornell, Elaine ^b   Wilson, Cara ^c   Ribeiro, Ruy M ^d   Ma, Dongzhu ^a   Kristoff, Jan ^a   Xu, Cuiling ^a   Haret Richter, George S ^a   Trichel, Anita ^a,e   Apetrei, Cristian ^a   Landay, Alan ^f   Tracy, Russell ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d LOS ALAMOS NATIONAL LABORATORY   (United States)

^e Division of Laboratory Animal Resources   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; ENDOTOXIN; THROMBIN ANTITHROMBIN COMPLEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CERCOCEBUS; CHLOROCEBUS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; HYPERCOAGULABILITY; INFLAMMATION; MACACA; MALE; MORTALITY; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS LOAD;

EID: 84865171842     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-414706     Document Type: Article

References (50)

1. Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS. 2011;6(4):266-271.
2. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203.
3. Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723- 1735.
4. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS. N Engl J Med. 1998;339(16):1093-1099. (Pubitemid 28465756)
5. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. AIDS Res Hum Retroviruses. 1998;14(12):1071-1077.
6. Blanchard DG, Hagenhoff C, Chow LC, McCann HA, Dittrich HC. Reversibility of cardiac abnormalities in human immunodeficiency virus (HIV)-infected individuals: a serial echocardiographic study. J Am Coll Cardiol. 1991;17(6):1270-1276.
7. Butt AA, Chang CC, Kuller L, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171(8):737-743.
8. Cohen IS, Anderson DW, Virmani R, et al. Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med. 1986;315(10):628-630. (Pubitemid 16046978)
9. De Castro S, d'Amati G, Gallo P, et al. Frequency of development of acute global left ventricular dysfunction in human immunodeficiency virus infection. J Am Coll Cardiol. 1994;24(4):1018-1024. (Pubitemid 24306413)
10. Jacob AJ, Sutherland GR, Bird AG, et al. Myocardial dysfunction in patients infected with HIV: prevalence and risk factors. Br Heart J. 1992;68(6):549-553. (Pubitemid 23001730)
11. Joshi VV, Pawel B, Connor E, et al. Arteriopathy in children with acquired immune deficiency syndrome. Pediatr Pathol. 1987;7(3):261-275.
12. Lipshultz SE, Chanock S, Sanders SP, Colan SD, Perez-Atayde A, McIntosh K. Cardiovascular manifestations of human immunodeficiency virus infection in infants and children. Am J Cardiol. 1989;63(20):1489-1497.
13. de Larrañaga GF, Petroni A, Deluchi G, Alonso BS, Benetucci JA. Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul Fibrinolysis. 2003;14(1):15-18.
14. Solages A, Vita JA, Thornton DJ, et al. Endothelial function in HIV-infected persons. Clin Infect Dis. 2006;42(9):1325-1332.
15. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) study 5152s. J Am Coll Cardiol. 2008;52(7):569-576.
16. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179(4):859-870. (Pubitemid 29159331)
17. Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr. 2002;29(4):346-355. (Pubitemid 34288887)
18. Rodríguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006;296(12):1498-1506.
19. Pandrea I, Sodora DL, Silvestri G, Apetrei C. Into the wild: simian immunodeficiency virus (SIV) infection in natural hosts. Trends Immunol. 2008;29(9):419-428.
20. Pandrea I, Apetrei C. Where the wild things are: pathogenesis of SIV infection in African nonhuman primate hosts. Curr HIV/AIDS Rep. 2010;7(1):28-36.
21. Pandrea I, Gaufin T, Brenchley JM, et al. Cutting edge: Experimentally induced immune activation in natural hosts of simian immunodeficiency virus induces significant increases in viral replication and CD4+ T cell depletion. J Immunol. 2008;181(10):6687-6691.
22. Pandrea IV, Gautam R, Ribeiro RM, et al. Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol. 2007;179(5):3035-3046.
23. Silvestri G, Paiardini M, Pandrea I, Lederman MM, Sodora DL. Understanding the benign nature of SIV infection in natural hosts. J Clin Invest. 2007;117(11):3148-3154. (Pubitemid 350096967)
24. Sodora DL, Silvestri G. Immune activation and AIDS pathogenesis. AIDS. 2008;22(4):439-446. (Pubitemid 351317285)
25. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187(10):1534-1543. (Pubitemid 36578959)
26. Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011;204(8):1217-1226.
27. Pandrea I, Onanga R, Kornfeld C, et al. High levels of SIVmnd-1 replication in chronically infected Mandrillus sphinx. Virology. 2003;317(1):119-127. (Pubitemid 37522233)
28. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol. 2006;7(3):235-239.
29. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365-1371. (Pubitemid 44924494)
30. Gordon SN, Klatt NR, Bosinger SE, et al. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol. 2007;179(5):3026-3034.
31. Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood. 2010;115(2):161-167.
32. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009;199(8):1177-1185.
33. National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
34. Pandrea I, Apetrei C, Dufour J, et al. Simian immunodeficiency virus SIVagm.sab infection of Caribbean African green monkeys: a new model for the study of SIV pathogenesis in natural hosts. J Virol. 2006;80(10):4858-4867.
35. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106(5):506-512. (Pubitemid 29231100)
36. Levy G. Value and limitations of the assay of a fibrin degradation product: D dimer. [article in French]. Sem Hop (Paris). 1987;63(25):2061-2064.
37. Twisk JWR. Applied Longitudinal Data Analysis for Epidemiology. Cambridge, United Kingdom: Cambridge University Press; 2003.
38. Diggle PJ, Heagerty P, Laing K-Y, Zeger SL. Analysis of Longitudinal Data. 2nd Ed. Oxford, United Kingdom: Oxford University Press; 2002.
39. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011;203(11):1637-1646.
40. Chalifoux LV, Simon MA, Pauley DR, MacKey JJ, Wyand MS, Ringler DJ. Arteriopathy in macaques infected with simian immunodeficiency virus. Lab Invest. 1992;67(3):338-349.
41. Eitner F, Cui Y, Hudkins KL, et al. Thrombotic microangiopathy in the HIV-2-infected macaque. Am J Pathol. 1999;155(2):649-661.
42. Shannon RP, Simon MA, Mathier MA, Geng YJ, Mankad S, Lackner AA. Dilated cardiomyopathy associated with simian AIDS in nonhuman primates. Circulation. 2000;101(2):185-193. (Pubitemid 30044259)
43. Yanai T, Lackner AA, Sakai H, Masegi T, Simon MA. Systemic arteriopathy in SIV-infected rhesus macaques (Macaca mulatta). J Med Primatol. 2006;35(2):106-112. (Pubitemid 43349103)
44. Chawla KK, Murthy CD, Chakravarti RN, Chhuttani PN. Arteriosclerosis and thrombosis in wild rhesus monkeys. Am Heart J. 1967;73(1):85-91.
45. Aristoteli LP, Moller HJ, Bailey B, Moestrup SK, Kritharides L. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis. 2006;184(2):342-347. (Pubitemid 43049718)
46. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011;204(8):1227-1236.
47. Pandrea I, Silvestri G, Onanga R, et al. Simian immunodeficiency viruses replication dynamics in African NHP hosts: common patterns and species-specific differences. J Med Primatol. 2006;35(4-5):194-201. (Pubitemid 44057343)
48. Picker LJ, Hagen SI, Lum R, et al. Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med. 2004;200(10):1299-1314. (Pubitemid 39552571)
49. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23(9):1059-1067.
50. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197(1):126-133. (Pubitemid 351263476)